Considering the possible interaction of nivolumab and mouse FcγRs, the effective anti-tumor T-cell reactions in huNOG-FcγR−/− mice, but not in huNOG mice, are reminiscent of a previous report by Arlaukas et.al.50. This evidence concerns the gene FCGR2A and neoplasm.